LUMO - Lumos Pharma Inc Stock Price, Fair Value and News

2.80USD+0.12 (+4.48%)Market Closed

Market Summary

USD2.80+0.12

Market Closed

4.48%

LUMO Stock Price

View Fullscreen

LUMO RSI Chart

LUMO Valuation

Market Cap

22.7M

Price/Earnings (Trailing)

-0.67

Price/Sales (Trailing)

11.07

EV/EBITDA

0.35

Price/Free Cashflow

-0.73

LUMO Price/Sales (Trailing)

LUMO Profitability

EBT Margin

-1705.36%

Return on Equity

-124.64%

Return on Assets

-83.75%

Free Cashflow Yield

-136.98%

LUMO Fundamentals

LUMO Revenue

Revenue (TTM)

2.1M

Rev. Growth (Yr)

61.33%

Rev. Growth (Qtr)

11.7K%

LUMO Earnings

Earnings (TTM)

-34.0M

Earnings Growth (Yr)

-14.67%

Earnings Growth (Qtr)

-13.94%

Breaking Down LUMO Revenue

Last 7 days

11.1%

Last 30 days

0.7%

Last 90 days

0.4%

Trailing 12 Months

-12.2%

How does LUMO drawdown profile look like?

LUMO Financial Health

Current Ratio

5.69

LUMO Investor Care

Buy Backs (1Y)

1.36%

Diluted EPS (TTM)

-4.18

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	2.1M	2.2M	1.7M	2.1M
2022	553.3K	876.5K	1.2M	1.5M
2021	0	188.7K	209.3K	230.0K
2020	744.0K	552.0K	360.0K	168.0K
2019	9.6M	6.7M	3.8M	936.0K
2018	35.9M	27.7M	22.4M	12.5M
2017	32.8M	41.2M	31.3M	28.7M
2016	35.0M	29.6M	30.7M	35.8M
2015	191.8M	210.9M	230.1M	68.5M
2014	1.1M	1.1M	86.8M	172.6M
2013	1.5M	1.2M	1.1M	1.1M
2012	1.7M	1.8M	1.7M	1.7M
2011	2.0M	2.0M	1.9M	1.9M
2010	0	0	1.5M	2.1M
2009	0	0	0	934.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Lumos Pharma Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 08, 2021	flynn james e	sold	-2,376,100	22.3083	-106,512	-
Jan 07, 2021	flynn james e	sold	-396,821	24.5376	-16,172	-
Jan 06, 2021	flynn james e	sold	-652,703	22.4768	-29,039	-

Which funds bought or sold LUMO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 17, 2024	Iron Horse Wealth Management, LLC	sold off	-	-	-	-%
Apr 11, 2024	West Financial Advisors, LLC	unchanged	-	-283	2,211	-%
Mar 11, 2024	VANGUARD GROUP INC	added	3.67	-761	776,181	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	100	1,244,400	2,586,050	-%
Feb 14, 2024	TWO SIGMA INVESTMENTS, LP	new	-	135,528	135,528	-%
Feb 14, 2024	Blackstone Inc.	reduced	-30.25	-506,444	1,038,440	-%
Feb 14, 2024	Royal Bank of Canada	reduced	-33.33	-	-	-%
Feb 14, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	unchanged	-	-8,099	149,123	-%
Feb 14, 2024	TWO SIGMA ADVISERS, LP	new	-	89,994	89,994	-%

Are Funds Buying or Selling LUMO?

Are funds buying LUMO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own LUMO

No. of Funds

Unveiling Lumos Pharma Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 09, 2024	goldman sachs group inc	5.1%	406,711	SC 13G/A
Feb 06, 2024	wells fargo & company/mn	5.3%	417,051	SC 13G
Nov 29, 2023	blackstone holdings ii l.p.	4.9%	385,683	SC 13D/A
Jun 20, 2023	farb daniel stuart	4.90%	4e+05	SC 13D/A
Jun 02, 2023	farb daniel stuart	6.08%	496,891	SC 13D/A
May 25, 2023	farb daniel stuart	7.87%	643,338	SC 13D/A
Feb 15, 2023	farb daniel stuart	9.07%	760,000	SC 13D
Feb 07, 2023	goldman sachs group inc	5.6%	469,402	SC 13G
Jan 24, 2023	farb daniel stuart	9.07%	760,000	SC 13G/A
Feb 02, 2022	farb daniel stuart	5.94%	496,811	SC 13G/A

Recent SEC filings of Lumos Pharma Inc

View All Filings

Date Filed	Form Type	Document
Apr 22, 2024	10-K/A	Annual Report
Apr 18, 2024	8-K	Current Report
Apr 15, 2024	ARS	ARS
Apr 12, 2024	DEF 14A	DEF 14A
Apr 12, 2024	DEFA14A	DEFA14A
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading

Peers (Alternatives to Lumos Pharma Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	2.33%	-21.90%	-8.74	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.4B	1.8B	-0.30%	-28.67%	-41.79	10.06	76.23%	61.08%
BMRN	17.4B	2.4B	8.14%	-4.26%	103.61	7.18	15.42%	18.43%
INCY	11.6B	3.7B	-9.39%	-31.39%	19.4	3.14	8.87%	75.42%
MID-CAP
APLS	5.9B	396.6M	-12.04%	-45.12%	-11.11	14.81	425.83%	18.94%
BBIO	4.5B	-	-13.93%	67.39%	-6.85	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-9.40%	-0.33%	-14.47	12.79	440.80%	-27.84%
ARWR	2.9B	240.7M	-12.61%	-20.79%	-9.93	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-6.74%	-16.88%	-45.01	3.8	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-6.36%	-10.84%	24.31	4.36	85.90%	-14.05%
NVAX	587.8M	983.7M	-10.64%	-48.02%	-1.08	0.6	-50.36%	17.16%
CRBP	396.0M	881.7K	8.01%	271.09%	-8.88	466.16	-77.61%	-5.33%
INO	242.4M	4.9M	-10.76%	0.48%	-1.79	49.8	-54.97%	51.71%
IBIO	6.7M	2.1M	76.15%	62.71%	-0.25	2.14	-13.45%	66.37%

Lumos Pharma Inc News

Latest updates

Lumos Pharma Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Revenue	11700.0%	826,000	7,000	527,000	691,000	512,000	497,000	403,000	111,000	93,250	75,500	57,750	40,000	74,000	33,000	233,000	433,000	246,000	151,000	176,500	202,000	120,000
Operating Expenses	21.2%	10,830,000	8,939,000	10,170,000	8,726,000	9,347,000	8,047,000	8,327,000	7,842,000	6,789,000	7,497,000	8,674,000	7,094,000	7,231,000	6,910,000	5,236,000	2,385,000	2,698,000	2,595,000	2,138,000	11,148,000	15,158,000
S&GA Expenses	7.2%	4,173,000	3,893,000	4,146,000	4,357,000	4,485,000	3,918,000	3,682,000	3,621,000	3,428,000	3,385,000	4,561,000	4,631,000	5,156,000	4,147,000	3,331,000	1,254,000	1,496,000	714,000	683,000	5,426,000	7,588,000
R&D Expenses	31.9%	6,657,000	5,046,000	6,024,000	4,369,000	4,862,000	4,129,000	4,645,000	4,221,000	3,361,000	4,112,000	4,113,000	2,463,000	2,075,000	2,763,000	1,905,000	1,131,000	1,202,000	1,881,000	1,455,000	5,722,000	7,570,000
EBITDA Margin	9.6%	-17.05	-18.85	-14.50	-14.09	-19.45	-24.11	-34.54	-56.11	-134	-149	-130	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-37,000	-	-	-40,000	-	-	48,000	-	-	-	-	1,000	2,000
Income Taxes	-	-	-	-29,000	-	-13,000	-	-	-	-636,000	-	-	-14,000,000	-2,432,000	-1,426,000	-5,463,000	-	-	-	-	27,500	-7,000,000
Earnings Before Taxes	-13.9%	-9,457,000	-8,300,000	-8,960,000	-	-8,260,000	-7,251,000	-7,844,000	-	-6,277,000	-7,488,000	-8,670,000	-7,067,000	-667,000	-6,779,000	-5,123,000	-2,362,000	-2,669,000	-2,569,000	-2,105,000	-10,546,000	-14,394,000
EBT Margin	9.6%	-17.05	-18.87	-14.51	-14.09	-19.46	-24.06	-34.55	-56.15	-135	-152	-132	-	-	-	-	-	-	-	-	-	-
Net Income	-13.9%	-9,457,000	-8,300,000	-8,931,000	-7,346,000	-8,247,000	-7,251,000	-7,844,000	-7,720,000	-5,641,000	-7,488,000	-8,670,000	-2,415,000	1,765,000	-5,353,000	340,000	-8,271,000	-2,669,000	-2,569,000	-2,105,000	-10,569,000	-7,403,000
Net Income Margin	12.2%	-16.59	-18.90	-14.27	-14.59	-20.40	-23.72	-32.74	-53.36	-132	-129	-95.15	-	-	-	-	-	-	-	-	-	-
Free Cashflow	5.5%	-7,393,000	-7,820,000	-6,685,000	-9,197,000	-5,826,000	-5,519,000	-7,245,000	-8,033,000	-5,811,000	-7,046,000	-6,379,000	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-14.9%	41.00	48.00	56.00	64.00	72.00	79.00	85.00	93.00	100	106	114	120	129	136	172	183	145	107	121	129	131
Current Assets	-15.6%	40.00	47.00	56.00	63.00	72.00	79.00	85.00	93.00	100	106	113	120	128	135	171	93.00	5.00	103	110	118	127
Cash Equivalents	-1.3%	35.00	36.00	38.00	44.00	56.00	74.00	80.00	87.00	95.00	101	108	114	99.00	106	73.00	86.00	5.00	8.00	10.00	12.00	14.00
Net PPE	-100.0%	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	0.00	3.00	3.00	4.00	4.00
Liabilities	8.8%	13.00	12.00	13.00	11.00	13.00	12.00	11.00	11.00	11.00	12.00	13.00	11.00	12.00	18.00	56.00	61.00	41.00	20.00	22.00	22.00	16.00
Current Liabilities	14.9%	7.00	6.00	7.00	5.00	7.00	5.00	5.00	5.00	5.00	6.00	7.00	5.00	6.00	7.00	43.00	47.00	1.00	14.00	9.00	9.00	9.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00	0.00	0.00
Shareholder's Equity	-23.1%	27.00	35.00	44.00	53.00	60.00	68.00	75.00	82.00	89.00	94.00	101	109	117	119	116	122	79.00	86.00	99.00	107	115
Retained Earnings	-6.2%	-161	-152	-143	-134	-127	-119	-111	-104	-96.42	-90.78	-83.29	-74.62	-65.99	-63.58	-65.34	-59.99	-59.68	-325	-311	-301	-291
Additional Paid-In Capital	0.7%	189	188	188	187	187	187	187	186	185	185	184	184	182	182	182	181	0.00	413	411	409	407
Shares Outstanding	2.4%	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	22.00	-	-	-	46.00	-	-	-	63.00	-	-	-	95.00	-	-	-	43.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	5.5%	-7,393	-7,820	-6,685	-9,197	-5,826	-5,519	-7,245	-8,033	-5,811	-7,046	-6,379	-10,412	-6,980	393	-13,100	-3,310	-2,733	-1,886	-2,285	-2,186	-1,317
Share Based Compensation	-6.3%	524	559	653	586	587	593	575	565	494	490	846	1,049	318	305	274	177	47.00	44.00	40.00	48.00	3,500
Cashflow From Investing	3.7%	6,172	5,950	1,083	-2,463	-11,358	-	-	-	-30.00	-	-	26,000	-12.00	32,496	-14.00	84,179	-2.00	-	-	-	6.00
Cashflow From Financing	270.6%	742	-435	-574	-309	-475	-326	-2.00	-18.00	-	-	-26.00	-166	96.00	-11.00	-10.00	-	22.00	-	46.00	-46.00	-12.00
Buy Backs	-100.0%	-	426	579	305	478	197	-	-	-	-	-	44.00	-	-	-	-	2.00	1.00	1.00	32.00	8.00

LUMO Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenues	$ 2,051	$ 1,523
Total revenues	2,051	1,523
Operating expenses:
Research and development	22,096	17,857
General and administrative	16,569	15,706
Total operating expenses	38,665	33,563
Loss from operations	(36,614)	(32,040)
Other income and expense:
Other income, net	683	91
Interest income	1,868	874
Other income, net	2,551	965
Net loss before taxes	(34,063)	(31,075)
Income tax benefit	29	13
Net loss	$ (34,034)	$ (31,062)
Net loss per share:
Basic (in dollars per share)	$ (4.18)	$ (3.71)
Diluted (in dollars per share)	$ (4.18)	$ (3.71)
Weighted average number of common shares outstanding
Basic (in shares)	8,145,155	8,373,821
Diluted (in shares)	8,145,155	8,373,821
Other comprehensive income (loss):
Unrealized gain (loss) on short-term investments	$ 9	$ (9)
Total comprehensive loss	$ (34,025)	$ (31,071)

LUMO Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 35,078	$ 56,007
Short-term investments	999	11,352
Prepaid expenses and other current assets	3,748	4,427
Other receivables	210	223
Total current assets	40,035	72,009
Non-current assets:
Property and equipment, net	0	53
Right-of-use asset	603	230
Total assets	40,638	72,292
Current liabilities:
Accounts payable	890	275
Accrued expenses	5,858	6,200
Current portion of lease liability	282	233
Total current liabilities	7,030	6,708
Long-term liabilities:
Royalty obligation payable to Iowa Economic Development Authority	6,000	6,000
Lease liability	303	0
Total liabilities	13,333	12,708
Commitments and contingencies
Stockholders' equity:
Undesignated preferred stock, $0.01 par value: Authorized shares - 5,000,000 at December 31, 2023 and 2022; issued and outstanding shares - 0 at December 31, 2023 and 2022	0	0
Common stock, $0.01 par value: Authorized shares - 75,000,000 at December 31, 2023 and 2022; issued shares - 8,125,728 and 8,283,708 at December 31, 2023 and 2022, respectively, and outstanding shares - 8,102,555 and 8,267,968 at December 31, 2023 and 2022, respectively	81	82
Treasury stock, at cost, 23,173 and 15,740 shares held as of December 31, 2023 and 2022, respectively	(196)	(170)
Additional paid-in capital	188,937	187,164
Accumulated deficit	(161,517)	(127,483)
Accumulated other comprehensive loss	0	(9)
Total stockholders’ equity	27,305	59,584
Total liabilities and stockholders’ equity	$ 40,638	$ 72,292

About Lumos Pharma Inc

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its primary product candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 3 clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.

CEO	Mr. Richard J. Hawkins
WEBSITE	https://lumos-pharma.com
INDUSTRY	Biotechnology
EMPLOYEES	32

Lumos Pharma Inc Frequently Asked Questions

What is the ticker symbol for Lumos Pharma Inc? What does LUMO stand for in stocks?

LUMO is the stock ticker symbol of Lumos Pharma Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Lumos Pharma Inc (LUMO)?

As of Tue Apr 23 2024, market cap of Lumos Pharma Inc is 22.7 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LUMO stock?

You can check LUMO's fair value in chart for subscribers.

What is the fair value of LUMO stock?

You can check LUMO's fair value in chart for subscribers. The fair value of Lumos Pharma Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Lumos Pharma Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LUMO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Lumos Pharma Inc a good stock to buy?

The fair value guage provides a quick view whether LUMO is over valued or under valued. Whether Lumos Pharma Inc is cheap or expensive depends on the assumptions which impact Lumos Pharma Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LUMO.

What is Lumos Pharma Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, LUMO's PE ratio (Price to Earnings) is -0.67 and Price to Sales (PS) ratio is 11.07. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LUMO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Lumos Pharma Inc's stock?

In the past 10 years, Lumos Pharma Inc has provided -0.182 (multiply by 100 for percentage) rate of return.